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induced radioresistance (HRS/IRR) response*
Charles Thomas1, Jennifer Martin1, Clément Devic1, Elke Bräuer-Krisch2, Michel Diserbo3, 
Juliette Thariat4 & Nicolas Foray1
1Institut National de la Santé et de la Recherche Médicale (INSERM) U 1052, groupe de radiobiologie, Lyon, 
2European Synchrotron Radiation Facility, Grenoble, 3Institut de Recherche Biomédicale des Armées (IRBA), BP 87,  
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example of a non-linear dose-dependent event. The HRS/
IRR response was originally observed in vivo in mice using 
acute skin tissue damage as an endpoint (Joiner et al. 
1986). Thereafter, the HRS response, mostly observed by 
using in vitro survival assay in single tumor cells, was 
shown to result in a significant reduction of about 25% cell 
survival between 0.1 and 0.8 Gy. The dose at which the 
maximal HRS response is observed (DHRSmax) depends on 
the cell line (Table I). The HRS response generally occurs 
in tumor or transformed cells (Marples and Collis 2008). 
At doses higher than DHRSmax, cell survival increases pro-
gressively and this phenomenon was called IRR response. 
Despite a number of studies, the mechanisms of the 
HRS and IRR responses, whether taken separately or 
together, remain unclear. It has been suggested that the 
HRS response may depend upon changes in chromatin 
conformation (Joiner et al. 2001), failure of the Ataxia 
Telangiectasia Mutated protein (ATM)-dependent G2/M 
checkpoint (Marples et al. 2004), or defects in DNA 
double-strand breaks (DSB) (Vaganay-Juery et al. 2000, 
Short et al. 2005). It was notably suggested that the HRS 
response may reflect apoptotic death of tumor cells that 
failed to arrest in cell cycle whereas the IRR response may 
reflect early cell cycle G2-phase arrest allowing time for 
repair and increased cell survival (Marples and Collis 
2008). In 2008, we pointed out that the HRS response 
may be caused by impairments in the non-homologous 
end-joining (NHEJ) repair pathway that targets G1 cells 
and in lack of control of the RAD51-dependent recombi-
nation repair pathway that targets S-G2/M cells; the con-
sequences of such impairments are failure to arrest in the 
cell cycle, propagation of damage through the cell cycle, 
mitotic death, but not p53-dependent apoptosis (Thomas 
et al. 2008).
he HRS/IRR response is more marked in cells displaying 
genomic instability: In fact, this response was mostly 
Abstract
Purpose: To ask whether dose-rate inluences low-dose hyper- 
radiosensitivity and induced radioresistance (HRS/IRR) response in 
rat colon carcinoma progressive (PRO) and regressive (REG) cells.
Methods: Clonogenic survival was applied to tumorigenic PRO 
and non-tumorigenic REG cells irradiated with 60Co g-rays at 
0.0025–500 mGy.min21. Both clonogenic survival and non-
homologous end-joining (NHEJ) pathway involved in DNA 
double-strand breaks (DSB) repair assays were applied to PRO 
cells irradiated at 25 mGy.min21 with 75 kV X-rays only.
Results: Irrespective of dose-rates, marked HRS/IRR responses 
were observed in PRO but not in REG cells. For PRO cells, the 
doses at which HRS and IRR responses are maximal were depen-
dent on dose-rate; conversely exposure times during which 
HRS and IRR responses are maximal (t
HRSmax
 and t
IRRmax
) were 
independent of dose-rate. The t
HRSmax
 and t
IRRmax
 values were 
23  5 s and 66  7 s (mean  standard error of the mean [SEM], 
n  7), in agreement with literature data. Repair data show 
that t
HRSmax
 may correspond to exposure time during which 
NHEJ is deicient while t
IRRmax
 may correspond to exposure time 
during which NHEJ is complete.
Conclusion: HRS response may be maximal if exposure times 
are shorter than t
HRSmax
 irrespective of dose, dose-rate and 
cellular model. Potential application of HRS response in radio-
therapy is discussed.
Keywords: Hyper-radiosensitivity (HRS) response, induced 
radioresistance (IRR) response, dose-rate, DSB repair, tumor 
cells, radiotherapy
Introduction
It is now well documented that cells irradiated at single 
low-dose fraction can show marked hyper-radiosensitivity 
(HRS) and induced radioresistance (IRR) response 
(Table I). The HRS/IRR response is a representative 
*he authors dedicate this work to Bernard Fertil for his contribution to radiobiology.
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Table I. Major radiobiological studies on HRS/IRR response. Most studies used tumor cell lines. Few studies used transformed cell lines 
(V79, CHO-K1, MR4, GM0639, EBS7YZ5) or a normal ibroblast cell line (BJ). he doses at which the maximal HRS and IRR response are observed 
(DHRSmax, DIRRmax) and the time at which the maximal HRS and IRR response are observed (tHRSmax, tIRRmax) were obtained from survival data 
reported in the quoted references.
Irradiation
Dose rate 
(mGy.min21)
DHRSmax 
(mGy) tHRSmax (s)
DIRRmax 
(mGy) tIRRmax (s) Cell line Reference
240 KV X-rays 180 200 67 600 200 Human HT29 Lambin et al. (1993)
240 KV X-rays 118 120 40 500 167 Human Be11 Lambin et al. (1996)
240 KV X-rays 180 250 83 500 167 Human RT112 Lambin et al. (1996)
60Co g-rays 580 200* 21 600 62 Human variant 1 
(T1p26)
homas et al. (1997)
60Co g-rays 580 100* 10 200 21 Human clone 4 (T1C3) homas et al. (1997)
60Co g-rays 1000 440 26 750 45 Rodent V79 Tsoulou et al. (2001)
9.5Mev a-rays 1000 340 20 500 30 Rodent V79 Tsoulou et al. (2001)
300 KV X-rays 500 110 13 500 60 Rodent subline CHO-K1 Barkowiak et al. (2001)
60Co g-rays 2000 100 3 500 15 Human BMG1 Chandna et al. (2002)
60Co g-rays 2000 200 6 500 15 Human U87 Chandna et al. (2002)
60Co g-rays 2000 300 9 500 15 Human PECA4451 Chandna et al. (2002)
60Co g-rays 2000 300 9 1000 30 Human PECA4197 Chandna et al. (2002)
10 MV X-rays 2430 800 20 950 23 Human G5 Beauchesne et al. 
(2003)
10 MV X-rays 2430 700 17 800 20 Human G111 Beauchesne et al. 
(2003)
10 MV X-rays 2430 700 17 950 23 Human G142 Beauchesne et al. 
(2003)
10 MV X-rays 2430 800 20 950 23 Human G152 Beauchesne et al. 
(2003)
137Cs g-rays 220 100 27 200 54 Human A549 Enns et al. (2004)
137Cs g-rays 220 250 68 750 205 Human T98G Enns et al. (2004)
320 KV X-rays 750 180 14 300 24 Rodent MR4 Wykes et al. (2006)
320 KV X-rays 750 105 8 400 32 Human M059K Wykes et al. (2006)
320 KV X-rays 750 140 11 400 32 Human EBS7YZ5 Wykes et al. (2006)
60Co g-rays 660 280 25 1000 91 Human T47D Edin et al. (2007)
320 KV X-rays 750 310 25 750 60 Human T98G Krueger et al. (2007a)
60Co g-rays 1800 100 3.3 300 10 Human BJ Nuta & Darroudi (2008)
60Co g-rays 500 190 23 500 60 Rodent PRO homas et al. (2008)
200 KV X-rays 500 100 12 300 36 Human GM0639 Xue et al. (2009)
290 Mev 6C 500 170 20 400 48 Human GM0639 Xue et al. (2009)
62 Mev protons 15000 2000 8 4000 16 Human HTB140 Petrovic et al. (2010)
250 KV X-rays 855 250 18 500 35 Human A549 Wera et al. (2012)
 
*hese numbers correspond to a reanalysis of our raw data for exposure times less than 10 min.
observed in tumor and in some transformed normal cell 
lines (Table I). Furthermore, we have previously reported 
that human and rodent tumorigenic cells with high meta-
static potential preferentially show the HRS response 
(homas et al. 1997, 2008). We have therefore suggested that 
the HRS response may ind applications in radiotherapy, 
notably for unvascularized and isolated micrometastasis 
(homas et al. 2001, 2007). On the other hand, the occur-
rence of the HRS/IRR response in primary normal cells is 
still controversial and may depend on the diferentiation 
and/or proliferation status. As an example, six among nine 
primary explants of uroepithelium showed HRS/IRR 
response with a 14 days post-irradiation proliferative assay 
as endpoint (Mothersill et al. 1995). he HRS/IRR response 
assessed by micronuclei assay was also observed in about 
10% of primary keratinocytes and ibroblasts from cervix 
carcinoma patients (Slonina et al. 2007).
Interestingly, the literature shows that the HRS/IRR 
response of tumor cells irradiated with low-energy transfer 
(LET) radiation was investigated at dose-rates ranging from 
0.18–2.43 Gy.min21 (Table I). hese data raise the question 
of a dose-rate-dependence of the HRS/IRR response. In 
order to answer this question, we investigated clonogenic 
cell survival at seven dose-rates (from 0.0025–500 mGy.
min21) in two rat colon carcinoma sublines progressive 
(PRO) and regressive (REG) cells that were shown to be HRS 
positive and negative, respectively (homas et al. 2008).
Materials and methods
Cells and irradiation
Rat colon carcinoma PRO and REG cells were kindly pro-
vided by Dr F. Martin (Dijon, France). PRO and REG sub-
lines were isolated from the parental tumor cell line 
DHD-K12, established from dimethylhydrazine-induced 
colon carcinoma in syngeneic BDIX rats (Martin et al. 
1983). PRO and REG sublines were isolated according to 
their sensitivity to trypsin-mediated detachment from 
plastic surface (PRO subline is more trypsin-resistant 
than REG subline). When grafted subcutaneously in BDIX 
rats, REG cells produced regressive tumors disappearing 
within 3–4 weeks while PRO cells produced progressive 
tumors in 60% of animals with metastases to lungs, 
kidney or lymph nodes (Martin et al. 1983). PRO and REG 
sublines were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 medium with 2 mM glutamine, 10% decom-
plemented fetal bovine serum, 1% [4-(2-hydroxyethyl)- 
1-piperazineethanesulfonic acid] (HEPES) and antibiotics 
(1% penicillin, streptomycin) (Gibco-Invitrogen-France, 
Cergy-Pontoise, France). Cells were mycoplasma-free and 
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 The HRS/IRR response does not depend on dose-rate 
maintained at 37°C at 5% CO2 for no more than ive pas-
sages after defrost. For all the assays described below, con-
luent PRO and REG cultures were softly detached with 
0.025% trypsin and 0.02% ethylenediaminetetraacetic acid 
(EDTA) (Gibco-Invitrogen-France, Cergy-Pontoise, France) 
to obtain single cell suspensions. Since the HRS/IRR 
response is suppressed under condition of increased cell-
cell contact (Chandna et al. 2002), the number of aggregates 
(no more than 5 cells) was kept as low as possible. Irradia-
tions were performed at European Synchrotron Radiation 
Facility (ESRF, Grenoble, France) with X-rays produced by a 
clinical irradiator (75 kV, 14 mA) at a dose-rate of 25 mGy/
min and at Institut de Recherche Biomédicale des Armées 
(IRBA, Grenoble, France) with 60Co g-rays at dose-rates of 
230, 60, 44, 25, 0.3 or 0.0025 mGy.min21. his range of dose-
rate corresponds to space radiation (0.0025 mGy.min21), 
nuclear medicine (0.3 mGy.min21), radiodiagnosis (25, 
44, 60 mGy.min21) and radiotherapy (230 mGy.min21). 
These four groups of dose-rate are evenly distributed on 
log scale. The 25 mGy.min21 dose-rate was chosen to 
evaluate cell survival at two different clinically relevant 
radiation type (Cobalt 60 g-rays and 75 kV X-rays). Dose 
and their homogeneity in the irradiation field were rou-
tinely verified with Physikalisch Technische Werkstatten 
(PTW) ionization chambers (0.3 cm3 type TM23332 for 
dose-rates higher than 25 mGy.min21 and 30 cm3 type 
TM23361 for dose-rates lower than 25 mGy.min21 at IRBA 
and semiflex chamber type TW31010–03907 for dose-rate 
of 25 mGy.min21 at ESRF). The relative dose error was 
10%. The error committed on exposure times (given digi-
tally) was negligible. For all the dose-rates applied in this 
study, the exposure times were always shorter than 10 min 
(Table II).
Clonogenic survival assay
Clonogenic survival was assessed as previously described 
(homas et al. 2008). Briely, 250 cells were seeded in six-
well plates and irradiated 24 h after plating at various 
dose-rates. Colonies were ixed and stained with standard 
crystal violet solution (Sigma-Aldrich-France, l’Isle d’Abeau, 
France) after 10 days incubation without change of medium. 
Only colonies showing more than 50 cells were considered. 
Plating eiciencies of unirradiated REG and PRO cells 
at IRBA were 39  6% (mean  standard error of the mean 
[SEM], n  8 independent experiments) and 25  2% 
(mean  SEM, n  17 independent experiments), respectively. 
Plating eiciencies of unirradiated REG and PRO cells at 
ESRF were 29  3% (mean  SEM, n  3 independent 
experiments) and 14  1% (mean  SEM, n  2 indepen-
dent experiments), respectively. he impact of cell prolifera-
tion before irradiation on HRS response was previously 
investigated; we showed that the HRS response was similar 
in PRO cells whether irradiated 2 or 24 h after plating; 
cell multiplicity (i.e., the number of cells per colony- 
forming unit) 24 h after plating was found to be close to 
one (homas et al. 2008).
Survival curves analysis
Using the JMP software (version 2.0.5. SAS institute, Cary, 
NC, USA), the surviving fractions (SF) were itted to two 
models: he one population linear-quadratic (LQ) model 
and the induced repair (IR) model (homas et al. 2008) 
deined by, respectively:
SF(D)  e2(a.D  b.D2) (1)
SF(D) e
r
s
r
D
dc
r
21 1 e D D

2   2 2
2








⋅ ⋅ ⋅
 
(2)
he IR model is a modiied version of the LQ model in 
which the a term is dependent on dose (D): at very low 
doses, a is large, and it decreases with increasing dose in 
an exponential manner at a rate determined by a constant 
dc. he parameter as represents the initial slope of the sur-
vival curve at very low doses; ar represents the initial slope 
of the survival curve extrapolated from the conventional 
high-dose response described by the LQ model; dc repre-
sents the dose that induced the change from HRS to IRR 
response and br represents the distal slope of the survival 
curve. he occurrence of the HRS/IRR response is mathe-
matically deduced from as and ar values that do not coin-
cide and dc values signiicantly greater than zero (Table II). 
Since some data reported in Table I were not always itted 
to the IR model, we deliberately chose to rename the dc 
parameter DHRSmax since it corresponds to the maximal 
extent of the HRS response. Similarly, we deined the DIRRmax 
parameter that corresponds to the maximal extent of the 
IRR response (Table I).
Immunoluorescence assay
he assay which is described elsewhere (homas et al. 
2008), was applied with minor modiications to measure 
the number of g-pH2AX foci per cell 15 min, 1 h , 4 h and 
24 h after irradiation. Briely, 104 cells were seeded on slides 
in six-well plates and incubated for 24 h in complete 
medium at 37°C. After irradiation at 75 kV X-rays at 10 mGy 
(24 s) and 100 mGy (240 s), plates were incubated at 37°C 
for 10 min and 24 h. Cells were then ixed in paraformal-
dehyde solution for 15 min at room temperature and per-
meabilized for 90 s at 4°C in lysis solution (20 mM HEPES) 
[pH 7.4], 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose, 
0.5% Triton X-100) (Sigma-Aldrich-France, l’Isle d’Abeau, 
France). Primary antibody incubations were performed 
for 40 min at 37°C. Anti-g-pH2AXser139 antibody (#05636; 
Upstate Biotechnology-Euromedex, Mundolsheim, France) 
was used at 1:800. Incubation with anti-mouse luorescein 
Table II. Dose-rates, exposure times and doses investigated in this 
study with 60Co g-rays (data shown in Figure 1A–F).
Dose-rate 
(mGy/min) Exposure times (s) Doses (mGy)
230 2.6; 6.5; 13; 26; 65; 78; 130 10; 25; 50; 100; 250; 300; 500
 60 5; 10; 25; 50; 100; 200; 
300; 500
5; 10; 25; 50; 100; 200; 300; 
500
 44 7; 14; 27; 70; 140; 270; 341 5; 10; 20; 50; 100; 200; 250
 25 6; 12; 24; 60; 120; 180; 240 2.5; 5; 10; 25; 50; 75; 100
0.3 5; 10; 20; 40; 100; 200 0.025; 0.05; 0.1; 0.2; 0.5, 1
0.0025 2.4; 6; 12; 24; 48; 120; 240 0.0001; 0.00025; 0.0005; 
0.001; 0.002; 0.005; 0.01
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Results
HRS/IRR response of PRO cells irradiated with 60Co g-rays
In 2008, we demonstrated the existence of a HRS/IRR 
response in PRO cells but not in REG cells irradiated at 
500 mGy.min21. he DHRSmax value that relects the transi-
tion between the HRS and IRR response (i.e., the lowest 
survival data) was 190 ( 8) mGy (homas et al. 2008). his 
dose corresponds to an exposure time of 23 ( 1) s at 
500 mGy.min21 (Table I). In order to examine whether dose-
rate inluences the HRS/IRR response, we investigated 
clonogenic survival of PRO cells irradiated at six diferent 
dose-rates between 0.0025 and 230 mGy.min21. For all the 
dose-rates applied in this study, a HRS/IRR response was 
systematically observed in PRO cells (Figure 1A–F). Since 
the distal part of the survival curves obtained at 0.3 and 
(green) secondary antibody was performed at 1:100 at 37°C 
for 20 min. Slides were mounted in 4′,6-diamidino-2-
phenylindole (DAPI)-stained Vectashield (Abcys, Paris, 
France) and the number of g-pH2AX foci per cell in 126-209 
cells (15 min experiments) or 142-198 cells (24 h experi-
ments) were examined with Olympus BX51 luorescence 
microscope. DAPI staining permitted to indirectly evaluate 
yield of G1 cells (nuclei with homogeneous DAPI staining), 
S cells (nuclei showing numerous g-pH2AX foci), G2  
cells (nuclei with heterogeneous DAPI staining) and meta-
phase (visible chromosomes). DAPI staining permitted also 
to quantify the percentage of cells with micronuclei by 
examining 100 cells at least. In order to avoid any bias by 
using imaging analysis software, the number of foci per cell 
was determined after eye-scoring in about 50 cells in G0/
G1 per slide.
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Figure 1. Impact of dose-rate on the HRS/IRR response. Survival curves of PRO cells (A–F) and REG cells (C and F) irradiated with cobalt 
60 g-rays at low-doses. Experiments were performed with cells cultured for no more than ive passages (p  5). Each data represents the mean  SEM 
of three (A), three (B), two (PRO cells) and two (REG cells) (C), two (D), four (E) and three (F) experiments for cells irradiated 24 h after plating. 
Six data points per dose are included in each experiment. Figures were itted to a smooth function. *p  0.05 for comparison between irradiated 
cells and unirradiated cells, using the t-test.
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 The HRS/IRR response does not depend on dose-rate 
0.0025 mGy.min21 showed negative br parameter with the 
IR model (Table III), all data were itted to a smooth function 
(Figure 1A–F). Irrespective of the dose-rates, the HRS/IRR 
response was observed systematically, but not at the same 
dose range. For example, the lowest survival was 86  1% 
irrespective of dose-rate, but DHRSmax ranged between 190 
mGy at 500 mGy.min21 and 0.00071 mGy at 0.0025 mGy.
min21 (Table IV). he DHRSmax values appeared to be a linear 
function of dose-rate with DHRSmax  0.4428  dose-rate 
(R2  0.89) (Figure 2A). he slope of this linear function cor-
responds to the exposure time required for the maximal 
HRS response. For convenience, we called it tHRSmax. Its 
average value was 0.4428  0.05 min or 26.57  3 s, and 
independent of dose-rate (Figure 2B). Similarly, if DIRRmax 
and tIRRmax are deined as the dose and the exposure time 
required for the maximal IRR response, respectively, our 
data showed that DIRRmax is linearly dependent on dose-rate 
with DIRRmax  0.997  dose-rate (R2  0.99) (Figure 2C). 
he slope tIRRmax was found to be 0.997  0.07 min or 
59.8  4.2 s, and independent of dose-rate (Figure 2D). 
hus, it appears that the maximal HRS and IRR responses 
in PRO cells correspond to exposure times that are inde-
pendent of dose-rates.
In agreement with our previous data obtained at 500 
mGy.min21, it is noteworthy that REG cells did not show 
marked HRS/IRR response at 44 mGy.min21 and 0.0025 
mGy.min21 (Figure 1C and 1F, respectively). Conversely, 
REG cells displayed signiicant radio-stimulation at 0.0025 
mGy.min21 (Figure 1F). Such very low dose-rate is known to 
stimulate the division potential in normal cells (e.g., Croute 
et al. 1986, Planel et al. 1987). However, these hormetic-like 
responses and their possible cellular mechanisms – that 
were recently reviewed (Szumiel 2012) – are beyond the 
scope of this paper (Supplementary Material to be found 
online at http://informahealthcare.com/abs/doi/10.3109/ 
09553002.2013.800248).
Comparison with the literature
We reviewed the HRS/IRR responses obtained in the litera-
ture from 1993–2012 (Table I). As a irst step, only low-LET 
radiation (X- and g-rays) data obtained at single dose-rate 
with short exposure times less than 10 min were considered. 
With regard to the HRS/IRR response parameters, no signii-
cant diference was observed between human and rodent 
cells. By pooling rodent and human data shown in Table I, 
the HRS/IRR responses were obtained at an average dose-
rate of 1000 mGy.min21. At such dose-rate, the DHRSmax and 
DIRRmax values obtained in the literature are in agreement 
with our data (Figure 1A and C). he tHRSmax value obtained 
in the literature [23  4 s (mean  SEM, n  25)] was not sig-
niicantly diferent from the experimental tHRSmax value 
obtained in this study [23.4  5.3 s (mean  SEM, n  7)] 
(Table IV). Similarly, the tIRRmax value obtained in the litera-
ture [59  12 s (mean  SEM, n  25)] was not signiicantly 
diferent from the experimental tIRRmax value obtained in 
this study [66  7.1 s (mean  SEM, n  7)] (Table IV). By 
pooling literature and our data, over a very large range of 
dose-rates (0.0025–2430 mGy.min21) tHRSmax and tIRRmax 
were found to be 23  3 s and 60  9 s [mean  SEM (n  32)], 
respectively.
HRS/IRR response of PRO cells irradiated with 75 kV X-rays
Since radiodiagnosis exams like computed tomography (CT) 
scans involve low-energy X-rays rather than high-energy 
g-rays, we examined whether the HRS/IRR response of PRO 
cells also exists with 75 kV X-rays. With regard to dose-rate, 
we chose to work at 25 mGy.min21 since this dose-rate 
Table III. Values of parameters obtained from the survival data it to the IR model; as represents the initial 
slope of the curve at very low doses; ar represents the low-dose slope of the survival curve extrapolated 
from high-doses; dc represents the dose that induced the change from HRS to IRR response and br 
represents the distal slope of the survival curve. Numbers in parentheses are the standard errors given 
by the JMP software; nc  no convergence.
as ar as/ar dc (mGy) br
Figure 1A 9.96 (2.1) 0.43 (0.23) 18 42 (8) 0.124 (0.5)
Figure 1B 21.8 (3.5) 0.21 (0.13) 106 21 (2.6) 0.21 (0.31)
Figure 1C (PRO cells) 17.2 (1.2) 0.5 (0.17) 34 23 (1.7) 0.11 (0.74)
Figure 1C (REG cells) nc nc nc nc nc
Figure 1D 31.5 (1.6) 1.5 (0.3) 21 11 (0.7) 1.22 (3.45)
Figure 1E 4.05 (0.69) 0.1 (0.03) 41 0.045 (0.006) 20.024 (0.033)
Figure 1F (PRO cells) 0.59 (0.2) 0.017 (0.016) 35 0.00071 (0.0002) 20.0006 (0.0018)
Figure 1F (REG cells) nc nc nc nc nc
Figure 3A (75 kV X-rays) 55.8 (5.7) 1.36 (1) 41 11 (1.2) 4.9 (10.4)
Figure 3A (60Co g-rays) 31.5 (1.6) 1.5 (0.3) 21 11 (0.7) 1.22 (3.45)
Table IV. Values of the HRS/IRR response parameters obtained with 
PRO cells irradiated with 60Co g-rays. DHRSmax and DIRRmax are the 
doses at which the maximal HRS and IRR response are observed, 
respectively; tHRSmax and tIRRmax are the time at which the maximal 
HRS and IRR response are observed, respectively.
Dose-rate 
(mGy.
min21)
DHRSmax 
(mGy)
tHRSmax 
(s)
DIRRmax 
(mGy)
tIRRmax 
(s)
500 190  8.1a
250b
23  1a
30b
500a
500b
60a
60b
230 42  8a
37  12b
11  2a
10  3b
175a
217  17b
46a
65  4b
 60 21  2a
28  12b
21  2a
28  12b
125a
83  17b
125a
83  17b
 44 23  2a
27b
31  3a
37b
100a
55b
136a
75b
 25 11  1a
17b
26  2b
41b
50a
38b
120a
91b
0.3 0.045  0.006a
0.031  0.006b
9  1a
6  1b
0.2a
0.19  0.1b
40a
38  20b
0.0025 0.00071  0.0002a
0.0005  0.00025b
17  5a
12  6b
0.004a
0.002  0.0009b
96a
48  22b
 
aParameters obtained from survival data it to the IR model. bExperimental 
parameters obtained from raw survival data shown in Figure 1 except those at 
500 mGy.min21 (taken from homas et al. 2008).
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foci ranged from 7–11 nuclear foci for both doses, the incu-
bation times at which it was reached difered signiicantly, 
i.e., 4 h and 1 h post-irradiation after a dose of 10 mGy and 
100 mGy, respectively. Furthermore, while the DSB repair is 
completed after 100 mGy, the DSB induced by 10 mGy 
appeared to be more severe with 5.5  0.7 residual g-H2AX 
foci 24 h after irradiation (Figure 3B). hese data suggest that 
tHRSmax may be associated with deicient NHEJ repair and 
maximal HRS response while tIRRmax may be associated with 
full NHEJ repair and maximal IRR response.
Discussion
Impact of dose-rate on the HRS/IRR response
By investigating one of the largest ranges of dose-rates 
applied in HRS/IRR studies, our data show that the maximal 
HRS and IRR responses obtained with low-LET radiation 
correspond to exposure times of about 20 s and 60 s, res-
pectively. To our knowledge, the impact of dose-rate and 
exposure time on the HRS/IRR response have not been 
investigated per se, notably with short exposure times less 
than 10 min. Exposure time is basically dependent on 
dose and dose-rate since these three parameters are linked 
mathematically. he dose-rates applied in the published 
studies ranging from 0.18–2.43 Gy.min21 (Table I), have 
rarely been explained: heir choice generally results from 
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Figure 2. Relationships between the HRS/IRR response experimental parameters (shown in Table IV) and the dose-rates in PRO cells. (A) Signiicant 
linear correlation between DHRSmax and dose-rate was found (y  0.4428.x, R2  0.89, p  0.05). (B) tHRSmax was not signiicantly correlated to 
dose-rate. (C) Signiicant linear correlation between DIRRmax and dose-rate was found (y  0.997.x, R2  0.99, p  0.05). (D) tIRRmax was not signi-
icantly correlated to dose-rate. Error bars indicate the SEM for n  2–4 independent experiments taken from Figures 1A–F (■) and for 25 indepen-
dent experiments obtained with low-LET radiation taken from Table I ( ).
generally applied in CT scan exams. Figure 3A shows that in 
the 5–100 mGy range, the HRS/IRR response occurs in PRO 
cells. Although the extent of the HRS response in PRO cells 
appeared to be larger with 75 kV X-rays than with 60Co g-rays, 
the survival data were not found signiicantly diferent (Fig-
ure 3A). Accordingly, the HRS and the IRR response param-
eters itted with the IR model were found similar with 75 kV 
X-rays and 60Co g-rays (Table III). Finally we conirmed that 
REG cells irradiated with 75 kV X-rays did not display signii-
cant HRS/IRR response (data not shown).
DSB repair features of HRS/IRR response
hereafter, by using 75 kV X-rays delivered at 25 mGy. 
min21, we examined the radiation-induced DSB relected by 
g-H2AX foci in two representative conditions: After 10 mGy, 
corresponding to the maximal HRS response (DHRSmax) and 
an exposure time lower than tHRSmax; after 100 mGy, corre-
sponding to dose higher than the maximal IRR response 
(doses higher than DIRRmax) and exposure time longer than 
tIRRmax. Figure 3B showed that for both doses, the kinetics of 
appearance/disappearance of g-H2AX foci elicited the same 
biphasic shape: (i) An increase of the number of g-H2AX foci 
corresponding to the recognition of radiation-induced 
DSB managed by NHEJ; (ii) a decrease of the number of 
g-H2AX foci corresponding to the repair of recognized 
DSB. However, while the maximal number of g-H2AX 
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Figure 3. HRS/IRR response of PRO cells irradiated with 75 kV X-rays. 
(A) Comparison between 60Co g-rays survival data (dashed line) 
and 75 kV X-rays survival data (continuous line). Experiments were 
performed with cells cultured for no more than 5 passages. Each data 
represents the mean  SEM of two independent experiments for cells 
irradiated 24 h after plating. Six data points per dose are included in 
each experiment. *p  0.05 for comparison between unirradiated cells 
and irradiated cells using the t-test. (B) Kinetic of DSB repair at 10 mGy 
(HRS response) or 100 mGy (IRR response). Each data represent the 
mean  SEM of 3–5 independent experiments for cells irradiated 24 h 
after plating. All data in Figure 3 were itted to a smooth function.
a practical compromise between the availabilities of the 
irradiator in the laboratory, a short exposure time to avoid 
artifacts and the possibility to expose cells during a minimal 
time. For example, some authors used several dose-rates for 
completing a single survival curve (e.g., Marples and Joiner 
1993, Martin et al. 2009). We deliberately chose not to 
include the studies using several dose-rates in our review 
shown in Table I. Similarly, HRS/IRR responses obtained 
with long exposure times (generally longer than 1 h) were 
not considered (e.g., Enns et al. 2004).
Some HRS/IRR responses were also observed with 
other radiation than X- or g-rays. his is notably the case of 
neutrons (Dionnet et al. 2000), a-rays (Tsoulou et al. 2001), 
protons (Petrovic et al. 2010), heavy ions (Xue et al. 
2009) and b-rays (Wéra et al. 2012). Interestingly, DHRSmax, 
DIRRmax, tHRSmax, tIRRmax are also in agreement with the 
values range of our review (Table I), which consolidates our 
conclusions showing that the maximal HRS and IRR 
responses would correspond, (by pooling literature and our 
data), to average exposure times of 31  8 s (SEM, n  35) 
and 58  9 s (SEM, n  35), respectively, irrespective of the 
radiation type (low and high-LET radiation). hus our data 
suggest that the HRS response is not limited to low-doses 
since tHRSmax can theoretically be reached with high-doses. 
Accordingly, tumor cells irradiated at 2 Gy with protons at 
15 Gy.min21 (exposure time  8 s) showed HRS response 
(Petrovic et al. 2010). However, since most HRS/IRR 
responses were obtained with low-LET radiation corre-
sponding to cell survival of 75  18 % (mean  SD, n  28) 
with doses ranging from 100–800 mGy (Table I), we stressed 
that the validity of the HRS/IRR response may not be 
relevant for higher doses and lower cell survival.
Biological signiicance of t
HRSmax
he indings that tHRSmax and tIRRmax are constant and com-
mon to human and rodent cells, tumor and transformed 
normal cells suggest that exposure times corresponding to 
the maximal HRS and IRR responses may not entirely 
depend on cellular parameters like cellular model or cell 
death pathways. Furthermore, a drastic decrease of cell sur-
vival was shown to be correlated with DSB repair impair-
ments with a number of cellular models and conditions 
(e.g., Joubert et al. 2008). In mammalian cells, DSB are 
mainly recognized and repaired by the NHEJ pathway. Par-
ticularly, alterations in NHEJ induce hyper-radiosensitivity 
at high-doses. his is the case of ATM-, ligase (LIG) 4-, DNA-
protein kinase (PK)-mutated cell lines that exhibit a survival 
fraction at 2 Gy (SF2) of about 1% (Joubert et al. 2008). 
Interestingly, the a parameter of the LQ model and 
the surviving fractions corresponding to these hyper- 
radiosensitive cell lines are very similar to those observed 
in the initial part of the survival curve in PRO cells and in 
other HRS-positive cell lines sorted in Table I. We suggest 
therefore that the [0–tHRSmax] exposure time interval may 
correspond to an incapacity of NHEJ to recognize and 
repair eiciently the induced DSB, as it is the case for the 
ATM-, LIG4-, DNA-PK-mutated cells. It was shown that the 
ATM kinase produces a cascade of phosphorylations of 
proteins involved in the radiation response (Foray et al. 
2003). he NHEJ repair pathway requires several steps such 
as: (i) DSB recognition, (ii) interaction between ATM and 
g-H2AX, and (iii) complete H2AX phosphorylation. In our 
hands, at least 10 min post-irradiation are required to observe 
the maximal number of g-H2AX foci. Besides, some authors 
applied 30 min post-irradiation to assess the number of rec-
ognized DSB (e.g., Joubert et al., 2008). Hence, DSB recogni-
tion and repair steps likely require much more than 20 s. 
Since residual DSB is observed 24 h after irradiation at 
10 mGy delivered either at 25 mGy.min21 (exposure time of 
24 s) (this study) or at 70 mGy.min21 (exposure time 8.5 s) 
(Grudzenski et al. 2010), we suggest that tHRSmax may be con-
sistent with the time corresponding to deicient NHEJ repair.
Biological signiicance of t
IRRmax
With regard to the second part of the survival curve ranging 
from tHRSmax to tIRRmax, an increase of cell survival is observed: 
induced-radioresistance (IRR) is the major interpretation 
of this part of the survival curve (Krueger et al. 2007b). 
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(Grudzenski et al. 2010)]. Altogether, our data are compatible 
with three exposure time phases and N-shaped dose- 
response curve regarding DSB and cell survival (Figure 4):
t  •  tHRSmax: Incomplete DSB recognition by NHEJ and 
decrease of cell survival (HRS response);
t • HRSmax  t  tIRRmax: Progressive activation of NHEJ and 
increase of cell survival (IRR response);
t  • . tIRRmax: All DSB are recognized but they are so numer-
ous that they cannot be all repaired; decrease of cell 
survival (beyond the HRS/IRR response).
he tIRRmax exposure time would therefore correspond to the 
time necessary for a fully active NHEJ pathway. Our data in 
Figure 3B show that NHEJ repair is complete 24 h after 
irradiation at 100 mGy delivered at 25 mGy.min21 which 
corresponds to an exposure time larger than tIRRmax. Accord-
ingly, tIRRmax may be compatible with kinetic of change in 
chromatin structure and nucleo-shuttling of pATM forms 
(Bakkenist and Kastan 2003), the earliest time to detect 
g-H2AX foci after irradiation (Rothkamm and Löbrich 2003) 
and the time required for induced repair after low-dose 
X-rays [e.g., 68 s or 80 mGy delivered at 70 mGy.min21 
Figure 4. Model for the HRS/IRR response. From 0 to DHRSmax, radiations induce physical DSB that are not all recognized biologically and 
therefore unrepaired. Consequently, cell survival decreases. From DHRSmax to DIRRmax, DSB are all recognized biologically and progressively 
repaired and cell survival increases. For doses higher than DIRRmax, DSB are all recognized but their amount is so large that some DSB are not 
repaired and cell survival decreases.
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Potential impact of the HRS/IRR response in radiotherapy
Our indings suggest that signiicant decrease of cell sur-
vival could be reached independently of dose-rate provided 
that exposure times are shorter than 30 s. his may be nota-
bly the case of the cyberknife™ radiotherapy technique that 
delivers non-uniform patterns of intermittent radiation 
using a compact miniaturized 6 MV nominal linear accel-
erator with high doses-rates of 4, 6 or 8 Gy.min21. he dose 
per fraction is delivered using 80–150 non-coplanar sequen-
tial mini-beams with  0.1% leakage at 1 m from the beam 
path. For example, for a dose per fraction of about 7 Gy to 
the brain, the peripheral dose is less than 5 mGy at 80 cm 
from the target (Di Betta et al. 2010). Interestingly, cyberknife 
delivers a single fraction of the total dose in 1–36 s with an 
interval between two beams of 5 s (Murphy et al. 2007). Fur-
thermore, Lin and Wu reported that not all 2 Gy fractions 
are equivalent: Human and rodent cells irradiated with 
60Co g-rays at 1.3–1.5 Gy.min21 in 10 fractions of 0.2 Gy 
(corresponding to about 8 s per fraction with an interval of 
16 s between fractions) showed higher radiosensitivity than 
a single fraction of 2 Gy (corresponding to an exposure time 
of 86 s at 1.4 Gy.min21) (Lin and Wu 2005). hus data sug-
gest that intermittent irradiation delivered in multiple frac-
tions or continuous irradiation delivered in a single fraction 
with exposure time per fraction shorter than 20 s may show 
maximal HRS response independently of dose-rate. How-
ever, further investigations are required to examine whether 
the time between fractions impacts signiicantly on the HRS 
response.
Finally and consistently with our previous reports (homas 
et al. 1997, 2001, 2007, 2008), we suggest that the HRS 
response may be relevant to target unvascularized microme-
tastases with peripheral doses received at a distance from the 
clinical target volume irradiated with intermittent radiation. 
In the context of oligometastatic disease, local ablative ste-
reotactic irradiation can be used to eradicate gross tumor 
while the potential microscopic disease is managed using 
systemic treatments (chemotherapy) or left untreated (har-
iat et al. 2012). We suggest that the HRS response driven by 
short exposure times such as used with stereotactic radio-
therapy may ind also application to manage micrometastatic 
disease at distance from the irradiated gross tumor. More 
experimental and clinical investigations with additional 
highly metastatic human cell lines will be needed to verify 
this medical hypothesis.
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Survival fraction data for PRO cells irradiated at 230 mGy/min 
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PRO cells D1.
Control 10 mGy 25 mGy 50 mGy 100 mGy 250 mGy 500 mGy
1.18 1.02 0.89 0.98 0.93 0.8 0.8
0.98 0.93 0.93 0.89 1.02 1.1 0.69
1.09 0.84 0.93 0.98 0.8 0.8 0.98
0.98 0.93 0.89 0.84 0.98 1.05 0.8
0.93 0.84 0.84 0.89 0.84 0.8 0.8
0.89 0.89 0.98 0.89 0.89 0.85 0.69
0.98 0.8 1 0.9 0.6 0.98 0.75
0.93 0.6 0.9 0.8 0.8 0.91 0.7
0.98 0.85 0.95 0.75 0.9 0.84 0.55
1.13 0.9 0.7 0.8 1 0.84 0.75
1.09 0.85 0.65 0.75 0.9 0.77 0.75
0.93 0.75 0.95 0.6 0.95 0.91 0.5
1 0.95 0.84 0.84 0.84 0.88
1 1.09 1.05 0.91 0.77 0.95
1.2 0.81 0.88 0.91 0.81 0.7
0.8 0.84 0.84 0.91 0.84 0.77
1.1 0.98 0.98 0.95 0.84 0.98
0.9 0.91 0.91 0.91 0.84 0.98
1.12
1.12
1.09
0.91
0.91
0.84
Supplementary material for homas C, et al. Impact of dose-rate on the low-dose hyper-radiosensitivity and induced 
radioresistance (HRS/IRR) response. International Journal of Radiation Biology, 2013; doi: 10.3109/09553002.2013.800248.
PRO cells D2.
Control 1 mGy 5 mGy 10 mGy 25 mGy 50 mGy 100 mGy 200 mGy 300 mGy 500 mGy
0.91 0.94 0.75 0.84 0.81 0.75 0.78 0.94 0.75 0.84
1.03 1.06 0.88 0.81 0.69 0.63 0.97 0.84 0.91 0.94
1 0.88 0.75 0.78 0.75 0.78 1.03 0.94 0.78 0.94
0.88 1 0.78 0.72 0.81 0.75 0.97 0.84 0.84 0.81
0.94 1.12 0.72 0.81 0.81 0.66 0.75 0.88 0.94 0.75
1.25 0.94 0.69 0.66 0.84 0.72 0.81 0.94 0.88 0.69
0.94 0.83 0.82 1 1.06 1 1.18 1 0.94 0.82
1.18 1 1 1.06 1.24 0.82 0.82 0.94 1.12 0.88
0.94 0.83 1 0.71 1.06 0.94 1.06 0.82 1.18 0.76
0.94 0.83 0.94 0.94 0.82 1 1 0.82 0.88 0.71
1.06 0.92 0.88 1.12 0.94 0.82 0.76 1.12 0.82 0.82
0.94 1.04 1 0.94 0.94 1.06 1 0.82 1 0.76
1 0.92 1 0.83 1.04 0.83 1.04 1 1
1.04 0.92 1 0.75 1 0.92 1.21 1 0.83
0.92 1 0.83 0.75 1 0.75 1.04 1 0.92
0.92 0.92 0.75 1 1.12 1 1 1.04 1
1.13 1 1 0.75 0.92 0.92 1 0.83 0.75
1 0.92 0.92 0.75 1.04 1 1 1 1
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PRO cells D3.
Control 5 mGy 10 mGy 20 mGy 50 mGy 100 mGy 200 mGy 250 mGy
1.04 0.95 0.96 0.86 0.72 0.88 0.9 0.72
1.2 1 0.88 0.9 0.8 0.76 0.88 0.96
1.2 1.05 0.8 1 0.8 0.76 0.9 0.88
1.04 0.86 0.8 0.9 0.8 0.88 0.95 0.8
0.88 0.9 0.8 0.86 0.76 0.76 0.95 0.88
1.28 1 0.8 0.9 0.8 0.8 1 0.8
0.88 1.05 0.95 0.72 0.9 1.1 0.98 0.92
1.04 0.85 0.95 0.92 0.81 1 0.92 0.85
0.8 0.85 0.86 0.72 0.86 1 0.79 0.98
0.88 0.72 0.86 0.85 1 1 0.85 0.92
0.96 0.85 0.9 0.82 0.95 0.9 0.85 0.72
0.96 0.92 0.86 0.92 0.95 1.05 0.92 0.98
0.95 1 1.05 0.83 0.85 0.92 1.08 1.25
1.05 1.17 0.98 0.92 0.85 0.79 1 0.96
0.9 0.92 0.98 0.92 0.85 0.85 1 0.83
1.05 0.83 0.85 1.08 0.92 0.79 1 0.92
1.1 1.08 0.72 0.92 0.85 0.79 0.83 0.92
0.95 0.83 0.85 1.17 0.85 0.89 1.08 1
0.92 0.65 0.88 1.22 1.17 0.92 1.04 0.83
1.1 0.96 0.92 1.09 1.25 0.96 0.87 0.74
0.98 1.22 0.88 0.91 1.08 1 0.91 1
0.92 0.87 1 1.04 0.92 0.83 1.13 0.96
1 0.96 1 0.96 1 0.92 0.74 0.91
1.17 0.91 1 1 1 0.92 1.3 0.91
0.92 1 0.91 0.95 0.87 1.09 1.24 1.07
1.04 1.02 1.13 0.95 1 1.22 1.24 0.95
1 0.95 1 1.19 0.96 0.83 1.07 0.83
0.92 1.07 1.22 0.95 1.09 0.83 0.88 0.95
1.04 1.19 1 1.95 1 1 1.07 0.95
1 0.9 1 1.19 0.96 1 1.07 1.19
1 0.95 1 1
0.92 0.95 1.07 1.19
1 1.07 1.07 0.95
0.83 1 0.95 0.95
1.17 0.95 1.19 0.9
1.04 1.07 1
1.09
1.13
1.04
0.83
1.09
0.96
1.13
0.83
1
0.96
0.82
0.87
1.09
0.87
1
0.96
1.07
0.95
0.95
0.98
1.24
1
1.07
0.9
1.09
1
0.95
0.98
1
0.95
0.95
0.98
0.95
1.07
PRO cells D5.
Control 0.025 mGy 0.05 mGy 0.1 mGy 0.2 mGy 0.5 mGy 1 mGy
1.17 0.91 0.78 1.09 1.04 1.04 0.91
1.04 0.87 1.04 0.83 1.04 0.96 0.91
1.09 0.83 1.04 0.91 0.91 0.78 0.74
1.13 0.87 1.04 1 0.96 0.87 0.83
1.04 0.91 0.87 0.87 1.13 0.87 1.09
0.83 0.87 1 0.96 0.96 0.78 1
1.09 1.17 0.91 0.78 0.96 1 0.65
0.96 0.96 0.83 0.96 0.83 0.91 0.91
1.13 0.91 1.04 1 0.87 0.91 0.87
0.83 0.78 0.87 0.65 0.87 0.96 0.96
1 0.65 1.09 0.74 1.04 0.61 0.91
0.96 0.96 0.83 0.74 0.87 0.78 0.87
0.83 1.14 1.05 1.12 1.02 0.98 1.07
0.87 1.02 1.02 1 1 0.98 1
1.09 0.93 1.07 1.19 1.07 0.95 1.1
0.87 0.98 1 0.95 1 1.14 1.02
1 0.9 1.02 1.07 0.95 1 1
0.96 1.12 1.07 1 0.95 1 1.05
1.07 0.94 1 0.7 1.03 0.9 0.7
0.95 1.03 0.7 1 1.03 0.9 0.7
0.95 1.13 0.6 0.95 1 0.95 0.7
0.98 0.86 0.6 0.7 1.03 0.85 0.8
1.24 0.84 0.75 0.8 1.06 0.8 0.75
1 0.96 0.85 0.95 1.03 0.9 0.85
1.07 1.13 1.23 1.08 1.23
0.9 1.09 0.97 1.13 0.92
1.09 0.97 0.87 1.18 0.97
1 0.97 1.03 0.92 1.13
0.95 0.92 1.13 1.23 1.08
0.98 0.94 1.18 1.03 1.03
1
0.95
0.95
0.98
0.95
1.07
1
1
1.2
0.8
1.1
0.9
1.02
0.97
0.92
1.13
0.97
0.97
PRO cells D4.
Control 2.5 mGy 5 mGy 10 mGy 25 mGy 50 mGy 75 mGy 100 mGy
1.1 0.96 0.74 0.96 0.74 0.96 0.9 0.74
0.96 0.92 0.74 0.81 0.81 0.89 0.9 0.81
1.1 0.96 0.89 0.74 0.74 0.96 0.76 0.81
0.89 0.81 0.81 0.74 0.96 0.81 0.88 0.89
1.04 1.1 1.04 0.81 0.74 0.89 0.86 0.81
0.93 0.92 0.89 0.78 0.78 0.81 0.9 0.85
1.05 0.95 1.05 0.9 1 0.95 0.95
1 0.86 1.05 0.95 0.86 0.9 0.86
1.1 0.9 1 0.95 1 0.93 0.9
1.1 0.95 0.95 1 0.95 0.95 0.88
0.86 0.9 0.9 1 1.05 0.93 0.86
0.9 0.9 0.93 0.81 1.05 0.9
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PRO cells D6.
Control 0.25 uGy 0.5 uGy 1 uGy 2 uGy 5 uGy 10 uGy
1 1 0.85 0.45 0.95 0.9 0.9
1 0.95 0.75 0.7 1.12 0.8 0.8
1.2 1.07 0.65 0.75 1.07 0.95 0.6
0.8 1 0.85 0.7 1 0.7 0.7
1.1 0.83 0.65 0.65 0.98 0.95 0.7
0.9 0.95 0.85 0.5 1.14 0.8 0.9
1.07 1 1.07 1 1.05 0.9 1.05
0.95 0.8 1.05 1 0.95 1 1.1
0.95 1 0.95 0.98 0.8 0.95 1.1
0.98 0.9 1.05 0.95 0.9 0.93 0.98
1.24 0.85 0.98 0.86 0.9 0.95 1.02
1 0.8 0.9 0.88 0.9 0.95 1.05
1.07 0.85 1 1.05 0.9
0.9 0.75 1.05 0.95 1
1.09 0.9 0.95 0.95 0.95
1 1 0.8 1 0.85
0.95 1 0.85 0.9 0.9
0.98 0.9 0.9 0.8 0.8
1
0.95
0.95
0.98
0.95
1.07
0.9
1.1
1.2
1
0.9
0.9
REG cells D3.
Control 5 mGy 10 mGy 20 mGy 50 mGy 100 mGy 200 mGy
1 1.13 1 1.07 0.93 0.93 1
0.9 1 1 1.07 1.1 0.9 1
1 0.93 1 1 1.07 1 1
1.07 1 1 1 1 0.9 1.07
1 1.07 1 1.07 1 0.93 1
1.07 0.93 1.13 0.87 0.87 0.8 1.13
1.19 0.97 1.3 0.97 0.97 0.97 0.86
0.97 0.86 0.86 0.97 0.81 0.97 0.92
1.08 1.08 1.08 0.86 0.97 1.03 0.81
0.92 0.86 1.08 0.92 1.03 0.76 0.97
0.86 1.14 0.97 1.03 0.92 1.19 0.92
0.97 0.86 0.76 0.97 0.86 1.08 0.97
REG cells D6.
Control 0.5 uGy 1 uGy 2 uGy 5 uGy 10 uGy
1.09 0.85 1.21 1.23 1.03 0.85
0.97 1.21 1.15 0.85 1.21 1.03
1.03 0.73 1.27 1.23 0.97 1.21
0.97 0.97 1.39 0.85 1.03 1.27
1.09 0.85 1.33 0.92 1.27 1.51
0.85 0.96 1.09 1.15 0.97 0.97
0.73 1.15 1.08 1.08 1.08 1.08
0.92 1.15 1.23 0.85 1.23 1.08
0.85 1.23 0.92 1.08 0.92 1.08
0.92 1.08 0.88 1.15 0.81 1.15
1 1.15 1.15 1.08 0.92 1.27
1.15 0.85 1.15 1 1.04
0.92 1 1.08 0.85 1.15
1 1 1.23 1.15 1.08
1.23 1.15 1.23 1.23 0.95
1.15 1.15 0.85 1 1.14
1 1 1 1.14 1.33
1 1.31 1.33 0.95
0.86 0.95 0.95
0.76 0.95 0.95
0.81 1.14
0.81 0.95
0.86
1.05
1.33
1.24
0.95
1.14
1.14
1.14
